For research use only. Not for therapeutic Use.
Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 (CB2) agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment[1].
| Catalog Number | R028194 |
| CAS Number | 916591-01-0 |
| Synonyms | (1R,7S)-N-tert-butyl-3-(2,4-difluorophenyl)-3,4-diazatricyclo[5.2.1.02,6]deca-2(6),4-diene-5-carboxamide |
| Molecular Formula | C19H21F2N3O |
| Purity | ≥95% |
| InChI | InChI=1S/C19H21F2N3O/c1-19(2,3)22-18(25)16-15-10-4-5-11(8-10)17(15)24(23-16)14-7-6-12(20)9-13(14)21/h6-7,9-11H,4-5,8H2,1-3H3,(H,22,25)/t10-,11+/m0/s1 |
| InChIKey | NTPZXHMTJGOMCJ-WDEREUQCSA-N |
| SMILES | CC(C)(C)NC(=O)C1=NN(C2=C1C3CCC2C3)C4=C(C=C(C=C4)F)F |
| Reference | [1]. Glenmark’s molecule for neuropathic pain, osteoarthritis – GRC 10693, successfully completes Phase I trials. |
